BrainsWay Ltd. (BWAY) P/E Ratio History
Deep ValueTrading at 23.4x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2024–2026
Loading P/E history...
P/E Ratio Analysis
As of November 8, 2026, BrainsWay Ltd. (BWAY) trades at a price-to-earnings ratio of 23.4x, with a stock price of $11.15 and trailing twelve-month earnings per share of $0.48.
The current P/E is 58% below its 5-year average of 56.4x. Over the past five years, BWAY's P/E has ranged from a low of 35.3x to a high of 149.8x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.6x, BWAY is roughly in line with its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 196.0x.
Relative to the broader market, BWAY trades roughly in line with the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our BWAY DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
BWAY Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
BWAY P/E vs Peers
Neuromodulation Devices peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $5B | 26.3 | - | -484% | |
| $225M | 20.9 | 0.57Best | +51% | |
| $191B | 40.6 | 4.91 | -51% | |
| $131B | 25.0 | 3.58 | +3% | |
| $64B | 17.8 | - | +55% | |
| $1B | 7.1Lowest | 0.69 | +817%Best | |
| $3B | 28.3 | 0.80 | -10% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
BWAY Historical P/E Data (2024–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | - | $15.51 | $0.44 | 35.3x | -37% |
| FY2026 Q1 | - | $13.29 | $0.35 | 38.0x | -33% |
| FY2025 Q4 | Dec 31 2025 | $9.51 | $0.25 | 38.0x | -33% |
| FY2025 Q3 | - | $7.54 | $0.15 | 49.9x | -12% |
| FY2025 Q2 | Jun 30 2025 | $6.58 | $0.15 | 43.5x | -23% |
| FY2025 Q1 | Mar 31 2025 | $4.74 | $0.12 | 39.1x | -31% |
| FY2024 Q4 | - | $4.72 | $0.10 | 45.2x | -20% |
| FY2024 Q3 | Sep 30 2024 | $4.62 | $0.07 | 68.8x | +22% |
| FY2024 Q2 | Jun 30 2024 | $3.04 | $0.02 | 149.8x | +166% |
Average P/E for displayed period: 56.4x
BWAY Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
2+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BWAY — Frequently Asked Questions
Quick answers to the most common questions about buying BWAY stock.
What is BWAY's P/E ratio?
BrainsWay Ltd. (BWAY) trailing twelve-month P/E ratio is 23.4x, based on TTM diluted EPS of $0.48. The 5-year average P/E is 56.4x and the historical range spans 35.3x to 149.8x.
Is BWAY stock overvalued or undervalued?
BWAY trades at 23.4x P/E, below its 5-year average of 56.4x. At the 0th percentile of its historical range (35.3x–149.8x), the stock is priced at a discount to its own history.
Is BWAY stock expensive?
No, BWAY is not expensive on a historical basis. The current P/E of 23.4x is below the 5-year average of 56.4x and sits at the 0th percentile of its valuation range.
What is BWAY's historical P/E range?
Over the past 5 years, BWAY's P/E ratio has ranged from 35.3x to 149.8x, with a median of 43.5x and an average of 56.4x. The current P/E of 23.4x places the stock at the 0th percentile of this range. Full historical data spans 2024–2026.
How does BWAY's P/E compare to the S&P 500?
BWAY trades at 23.4x P/E versus the S&P 500 median of 21.8x. The 7% premium to the market typically reflects higher expected earnings growth or quality.
How does BWAY's valuation compare to Healthcare peers?
BrainsWay Ltd. P/E of 23.4x compares to the Healthcare sector median of 24.6x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is BWAY's PEG ratio?
BWAY PEG ratio is N/A, based on a P/E of 23.4x and EPS growth of 300.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is BWAY's earnings yield?
BWAY earnings yield is 4.27%, the inverse of its 23.4x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.